NMZL
MCID: NDL020
MIFTS: 34

Nodal Marginal Zone B-Cell Lymphoma (NMZL)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Nodal Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Nodal Marginal Zone B-Cell Lymphoma:

Name: Nodal Marginal Zone B-Cell Lymphoma 58
Monocytoid B-Cell Lymphoma 71
Nmzl 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C83.0
Orphanet 58 ORPHA86867
UMLS 71 C0855139

Summaries for Nodal Marginal Zone B-Cell Lymphoma

MalaCards based summary : Nodal Marginal Zone B-Cell Lymphoma, also known as monocytoid b-cell lymphoma, is related to marginal zone b-cell lymphoma and b-cell lymphoma. An important gene associated with Nodal Marginal Zone B-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are NF-kappaB Signaling and Notch Signaling Pathway (WikiPathways). The drugs Thiotepa and Pixantrone have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow.

Related Diseases for Nodal Marginal Zone B-Cell Lymphoma

Diseases related to Nodal Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 marginal zone b-cell lymphoma 31.3 MALT1 BCL6
2 b-cell lymphoma 30.4 MALT1 BCL6 BCL2
3 follicular lymphoma 30.3 BCL6 BCL2
4 lymphoma 30.1 MALT1 BCL6 BCL2
5 diffuse large b-cell lymphoma 30.1 MALT1 BCL6
6 lymphoma, mucosa-associated lymphoid type 29.7 MALT1 BCL6 BCL2
7 mantle cell lymphoma 29.2 MALT1 BCL6 BCL2
8 nodal marginal zone lymphoma 10.5
9 hepatitis c virus 10.4
10 lymphoplasmacytic lymphoma 10.4
11 posttransplant acute limbic encephalitis 10.4
12 leukemia, acute myeloid 10.2
13 myelodysplastic syndrome 10.2
14 mulchandani-bhoj-conlin syndrome 10.2
15 lymphoproliferative syndrome 10.2
16 neutropenia 10.2
17 lymphadenitis 10.2
18 hepatitis c 10.2
19 keratopathy 10.2
20 plasmacytoma 10.2
21 composite lymphoma 10.2
22 dacryoadenitis 10.2
23 47,xyy 10.2
24 chronic myelomonocytic leukemia 10.2
25 leukemia 10.2
26 gallbladder lymphoma 9.9 MALT1 BCL6
27 lung lymphoma 9.9 MALT1 BCL6
28 gastrointestinal lymphoma 9.9 MALT1 BCL6
29 central nervous system lymphoma 9.8 MALT1 BCL6
30 spleen cancer 9.8 MALT1 BCL6
31 gastric lymphoma 9.8 MALT1 BCL6
32 splenic marginal zone lymphoma 9.7 MALT1 BCL6
33 sezary's disease 9.7 MALT1 BCL6
34 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 9.7 BCL6 BCL2
35 primary mediastinal large b-cell lymphoma 9.7 BCL6 BCL2
36 intravascular large b-cell lymphoma 9.7 BCL6 BCL2
37 follicular lymphoma 1 9.6 BCL6 BCL2
38 cheilitis 9.6 MALT1 BCL2
39 human herpesvirus 8 9.6 BCL6 BCL2
40 lymphosarcoma 9.6 BCL6 BCL2
41 primary central nervous system lymphoma 9.6 BCL6 BCL2
42 intraocular lymphoma 9.6 BCL6 BCL2
43 reticulosarcoma 9.5 BCL6 BCL2
44 lymphoma, hodgkin, classic 9.4 BCL6 BCL2
45 wilms tumor 1 9.3 BCL6 BCL2
46 burkitt lymphoma 9.2 BCL6 BCL2
47 lymphoma, non-hodgkin, familial 9.1 MALT1 BCL6 BCL2

Graphical network of the top 20 diseases related to Nodal Marginal Zone B-Cell Lymphoma:



Diseases related to Nodal Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Nodal Marginal Zone B-Cell Lymphoma

Drugs & Therapeutics for Nodal Marginal Zone B-Cell Lymphoma

Drugs for Nodal Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Pixantrone Approved, Investigational Phase 3 144510-96-3
3
Chlorambucil Approved Phase 3 305-03-3 2708
4
Idarubicin Approved Phase 3 58957-92-9 42890
5 Orange Approved Phase 3
6
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
9
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
10
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
13
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
14
Dalteparin Approved Phase 3 9005-49-6
15
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Captopril Approved Phase 3 62571-86-2 44093
19
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
20
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
21
Ribavirin Approved Phase 3 36791-04-5 37542
22
Palivizumab Approved, Investigational Phase 3 188039-54-5
23
Acyclovir Approved Phase 3 59277-89-3 2022
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
26
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
27
Tazobactam Approved Phase 3 89786-04-9 123630
28
Vancomycin Approved Phase 3 1404-90-6 14969 441141
29
Piperacillin Approved Phase 3 66258-76-2 43672
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
31
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
32
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
33
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
34
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
35
Polyestradiol phosphate Approved Phase 3 28014-46-2
36
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
37
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
38
Epratuzumab Investigational Phase 2, Phase 3 205923-57-5
39 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
40 Ferric Oxide, Saccharated Phase 3
41 Dextrans Phase 3
42 Plasma Substitutes Phase 3
43 Iron-Dextran Complex Phase 3
44 Blood Substitutes Phase 3
45 Anesthetics, Dissociative Phase 3
46 Adjuvants, Immunologic Phase 3
47 Antibodies Phase 3
48 Immunoglobulins Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Tubulin Modulators Phase 3

Interventional clinical trials:

(show top 50) (show all 366)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
3 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
4 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
5 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
6 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
7 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
8 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
9 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
10 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
11 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
13 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
14 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
16 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
17 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
18 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
19 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
20 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
21 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
22 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
23 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
24 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
25 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
26 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
27 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
28 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
29 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
30 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
31 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
32 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
33 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
34 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
35 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
38 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
39 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
40 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
41 Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Active, not recruiting NCT00075946 Phase 3
42 A Phase III Randomized Study On Low-Dose Total Body Irradiation And Involved Field Radiotherapy In Patients With Localized, Stages I and II, Low Grade Non-Hodgkin's Lymphoma Terminated NCT00014326 Phase 3
43 Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) for GVHD Prophylaxis Terminated NCT00003056 Phase 3 cyclosporine;cyclosporine and methotrexate
44 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
45 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
46 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma Unknown status NCT00007839 Phase 1, Phase 2 beta alethine
47 Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia Unknown status NCT00003885 Phase 2 arsenic trioxide
48 Phase II Study of High-Dose Cytarabine, Cisplatin, and Dexamethasone Followed By Cyclophosphamide, Etoposide, Total Body Irradiation, and Autologous Bone Marrow Rescue in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Unknown status NCT00002481 Phase 2 cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide
49 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
50 Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate

Search NIH Clinical Center for Nodal Marginal Zone B-Cell Lymphoma

Genetic Tests for Nodal Marginal Zone B-Cell Lymphoma

Anatomical Context for Nodal Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Nodal Marginal Zone B-Cell Lymphoma:

40
B Cells, Bone, Bone Marrow, T Cells, Liver, Breast, Myeloid

Publications for Nodal Marginal Zone B-Cell Lymphoma

Articles related to Nodal Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 135)
# Title Authors PMID Year
1
Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall. 61
31764221 2020
2
90 Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study. 61
31944265 2020
3
Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma. 61
31804739 2020
4
[Transformation of CD5-positive nodal marginal zone lymphoma to diffuse large B-cell lymphoma]. 61
32224585 2020
5
Contemporary management of nodal and primary splenic marginal zone lymphoma. 61
31619091 2019
6
IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications. 61
31802229 2019
7
Predictive markers of lymphomagenesis in Sjögren's syndrome: From clinical data to molecular stratification. 61
31431317 2019
8
A case of nodal marginal zone lymphoma with hypersensitivity to mosquito bites as initial symptom. 61
31095761 2019
9
Primary hyaline vascular Castleman disease of the kidney: case report and literature review. 61
31439011 2019
10
[Paediatric nodal marginal zone lymphoma: a clinicopathological study of seven cases]. 61
31104676 2019
11
Rapid Regression of B-Cell Non-Hodgkin's Lymphoma after Eradication of Hepatitis C Virus by Direct Antiviral Agents. 61
31543755 2019
12
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. 61
30484876 2019
13
FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. 61
30734341 2019
14
Prognostic significance of peripheral blood and bone marrow infiltration in newly-diagnosed canine nodal marginal zone lymphoma. 61
30902194 2019
15
[Simultaneous Laparoscopic Sigmoid Colectomy and Malignant Lymphoma Biopsy-A Case Report]. 61
30914601 2019
16
Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma-A case report. 61
30385086 2019
17
Case of Gastric Diffuse Large B-Cell Lymphoma. 61
31043941 2019
18
A patient with a diagnosis of nodal marginal zone B-cell lymphoma and a t(2;14)(p24;q32) involving MYCN and IGH. 61
30733831 2019
19
High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. 61
29556019 2018
20
A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL). 61
30254190 2018
21
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. 61
29984825 2018
22
Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour. 61
29205839 2018
23
Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. 61
29286565 2018
24
Simultaneous Occurrence of Rosai-Dorfman Disease and Nodal Marginal Zone Lymphoma in a Patient with Sjögren's Syndrome. 61
30305966 2018
25
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. 61
27443419 2017
26
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. 61
29222281 2017
27
Results of Upfront Therapy for Marginal Zone Lymphoma. 61
29042174 2017
28
Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. 61
28280994 2017
29
Analysis of Clinical Characteristics for 24 Cases of Nodal Marginal Zone Lymphoma. 61
28483023 2017
30
Pathology of nodal marginal zone lymphomas. 61
28288717 2017
31
Molecular pathogenesis of splenic and nodal marginal zone lymphoma. 61
28288716 2017
32
Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment. 61
28288722 2017
33
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. 61
27389974 2017
34
Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications. 61
27297871 2017
35
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. 61
27443247 2016
36
The genetics of nodal marginal zone lymphoma. 61
27335277 2016
37
Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. 61
26694256 2016
38
Optimizing therapy for nodal marginal zone lymphoma. 61
26989202 2016
39
Misdiagnosis of primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, a case report. 61
26956381 2016
40
A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma. 61
26949422 2016
41
Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. 61
26636329 2016
42
Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. 61
26416032 2016
43
An unusual presentation of gastric mucosa-associated lymphoid tissue (MALT)-type lymphoma. 61
27609718 2016
44
Composite Follicular Lymphoma and CD5-Positive Nodal Marginal Zone Lymphoma. 61
27334859 2016
45
[Low grade lymphoma: research progress and questions about treatment]. 61
26458443 2015
46
Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. 61
26275804 2015
47
Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review. 61
26185372 2015
48
MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. 61
25723115 2015
49
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. 61
24956144 2015
50
Childhood nodal marginal zone lymphoma with unusual clinicopathologic and cytogenetic features for the pediatric variant: a case report. 61
25625642 2015

Variations for Nodal Marginal Zone B-Cell Lymphoma

Expression for Nodal Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Nodal Marginal Zone B-Cell Lymphoma.

Pathways for Nodal Marginal Zone B-Cell Lymphoma

GO Terms for Nodal Marginal Zone B-Cell Lymphoma

Biological processes related to Nodal Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.4 BCL6 BCL2
2 negative regulation of cell growth GO:0030308 9.37 BCL6 BCL2
3 negative regulation of apoptotic process GO:0043066 9.33 MALT1 BCL6 BCL2
4 cell morphogenesis GO:0000902 9.32 BCL6 BCL2
5 B cell differentiation GO:0030183 9.26 BCL6 BCL2
6 positive regulation of B cell proliferation GO:0030890 8.96 BCL6 BCL2
7 regulation of apoptotic process GO:0042981 8.8 MALT1 BCL6 BCL2

Molecular functions related to Nodal Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.13 MALT1 BCL6 BCL2
2 protease binding GO:0002020 8.62 MALT1 BCL2

Sources for Nodal Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....